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Purpose of the study
To investigate the epidemiology and outcome of HIV-
infected patients (pts) with acute hepatitis C virus (HCV)
infection.
Methods
The medical files of all HIV/HCV co-infected pts followed
at the clinic of the Antwerp Institute of Tropical Medicine
(ITM) from January 2000 to June 2008 were reviewed.
Acute HCV infection was defined as a confirmed HCV
antibody seroconversion and a ≥5 times upper normal
limit elevation of transaminases.
Summary of results
2,188 pts with HIV infection were followed during the
study period. Of them 161 (7%) were identified with an
HCV infection including 37 (23%) with an acute HCV
infection. The incidence of acute HCV infection increased
from 0.13/100 pts/year in 2000 to 0.91/100 pts/year in
2007. All pts with an acute HCV infection were MSM of
European origin. Thirty were infected with HIV prior to
the HCV infection, seven were diagnosed with HIV and
HCV concomitantly. Thirty-four (92%) had a docu-
mented episode of at least one other STD within 6 months
prior to HCV diagnosis. One pt died of non-Hodgkin lym-
phoma 3 years after the diagnosis of HCV, five are lost to
follow-up (LTFU) and all others are still alive in 2008.
Thirty-three of the 37 pts received HAART, but this treat-
ment had to be interrupted or modified in 12 pts (36%)
during the HCV infection.
Genotyping was performed in 33 pts: 21 with genotype 1
(64%) and 12 with genotype 4 (36%); 22 pts underwent
a liver biopsy with a median of 149 days (interquartile
range, IQR, 156 days) after HCV diagnosis. Moderate to
severe fibrosis (Metavir ≥F2) was observed in 10 pts
(45%).
Combined treatment with pegylated interferon-α and rib-
avirin was initiated in 14 pts (38%) after a median of 339
days (IQR 229 days). In June 2008, five pts were still
under HCV treatment. Only one of the remaining pts
achieved sustained virological response. Of note, we
observed three cases of spontaneous recovery and four
possible cases of re-infection.
Conclusion
Acute HCV infection is increasingly diagnosed among
MSM in our cohort and interfered frequently with HAART.
Evolution to liver fibrosis was rapid in a substantial pro-
portion of the study population. HCV treatment rate and
treatment success were low. MSM need more counseling
about the risk of (re-) acquiring HCV infection and HCV
screening should be reinforced in the 6 months after STD
diagnosis.
from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008
Published: 10 November 2008
Journal of the International AIDS Society 2008, 11(Suppl 1):P270 doi:10.1186/1758-2652-11-S1-P270
<supplement> <title> <p>Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1758-2652-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf</url> </supplement>
This abstract is available from: http://www.jiasociety.org/content/11/S1/P270
© 2008 Florence et al; licensee BioMed Central Ltd. 
